Abstracts tagged "Compliance and rheumatoid arthritis (RA)"

Abstract Number: 434 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Treatment Adherence in Rheumatoid Arthritis: A Systematic Literature Review
Ee Teng Goh¹, Alvin Jian Xiong Soo¹, James Galloway², Sam Norton³ and Elena Nikiphorou⁴, ¹UCL Medical School, University College London, London, United Kingdom, ²King's College, and King´s College Hospital, London, United Kingdom, ³Academic Rheumatology, King´s College London, London, United Kingdom, ⁴Academic Rheumatology Department, King's College London, London, United Kingdom
Background/Purpose: Nonadherence to treatment in rheumatoid arthritis (RA) has been shown to negatively impact on treat to target goals and disease outcomes. Identifying and targeting…
Abstract Number: 2530 • 2016 ACR/ARHP Annual Meeting
Patient´s Motivations for Non-Persistence with Medication Impact How They Score Compliance
Irazú Contreras-Yáñez¹, Diana Isabel Pérez-Román² and Virginia Pascual-Ramos³, ¹Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology., Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán., Mexico City, Mexico, ³Mexican Accreditation Council of Rheumatology, A.C., Mexico City, Mexico
Background/Purpose: In 2004 we initiated a cohort of rheumatoid arthritis (RA) patients with recent-onset disease. From 2008 onwards, both construct of compliance, persistence on therapy…
Abstract Number: 2261 • 2013 ACR/ARHP Annual Meeting
Motivations For Inadequate Persistence With Disease Modifying Anti-Rheumatic Drugs In Early Rheumatoid Arthritis: The Patient’s Perspective
Virginia Pascual-Ramos and Irazú Contreras-Yáñez, Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Knowledge of factors that contribute to non-persistence with disease modifying anti-rheumatic drugs (NP-DMARDs) is essential to improve rheumatoid arthritis (RA) outcomes. Aims of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].